πŸ”₯Game Changer

Broadening the Horizon of Precision Editing with flexiAsCas12a, a Gene Editor Free from Strict Target Sequence Constraints

Genome biologyΒ·November 21, 2026AI Curation
Broadening the Horizon of Precision Editing with flexiAsCas12a, a Gene Editor Free from Strict Target Sequence Constraints
✨AI Summary (Beta)Beta

Background

In the field of genome editing, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has shifted the paradigm of genetic disease treatment and life science research. The emergence of Prime Editing (PE) technology, which allows for precise base substitution, insertion, or deletion without inducing Double-Strand Breaks (DSB), has further enhanced the potential for precision genome editing. Beyond the widely used Cas9 protein, the Cas12a enzyme is gaining attention for its unique properties, such as creating staggered DNA cuts and its ability to process its own crRNA, which is advantageous for multiplex gene targeting.

However, Cas12a has very strict Protospacer Adjacent Motif (PAM) sequence requirements essential for target DNA recognition. Typical Cas12a requires a TTTV motif (where V is A, C, or G), characterized by consecutive thymines (T) preceding the target sequence. In genomic regions with low adenine (A) and thymine (T) content, or at specific disease-associated mutation sites, suitable binding sites may be absent, making it difficult to target them for therapy. Despite its potential as a precision editing tool, its narrow targeting range has remained a long-standing obstacle in mammalian cell research and therapeutic development.

Key Findings

Researchers focused on expanding the target range to previously inaccessible genomic regions by increasing the recognition flexibility of the Cas12a protein. Based on the structures of Cas12a derived from various strains (LbCas12a, AsCas12a, MbCas12a, FnCas12a), novel variants were designed through protein engineering, and their actual cleavage activities in mammalian cells were compared and verified.

Among the selected candidates, flexiAsCas12a, which improved the sequence recognition site of AsCas12a, exhibited the most outstanding target expansion performance. This enzyme variant significantly relaxed the constraint of consecutive thymine arrays that conventional Cas12a absolutely required. Experimental results showed that flexiAsCas12a effectively recognized and cleaved target strands not only at its inherent target sites but also at non-canonical PAM sequences rich in guanine (G) or cytosine (C), such as NATN, NCCN, and GTCN. The significant expansion of the recognizable sequence spectrum has enabled the identification of new target regions within disease-related genes that were previously inaccessible to conventional Cas12a.

To connect this expanded PAM recognition capability to an actual precision genome editing tool, the researchers constructed a Circular RNA (circRNA)-based Split Prime Editor system. They loaded three Cas12a variants with improved binding flexibility (impLbCas12a, flexiAsCas12a, and enAsCas12a) into this system to precisely measure editing efficiency at non-canonical PAM positions. These editors, combined with highly stable circRNA guides, maintained binding affinity even at non-canonical target sequences and successfully induced intended base editing. We have developed a unique toolkit to address the limitations of previously reported Cas12a variants.

Significance and Outlook

This achievement holds academic value by overcoming the targeting limitations of Cas12a-based gene editors and directly expanding their application scope to next-generation prime editing platforms. A pathway has opened to enable the use of Cas12a for base editing targets that previously relied on Cas9 due to restrictive PAM sequences. With the assurance of target flexibility, Cas12a’s characteristic low off-target cleavage rate and its advantages in multiplexed editing are expected to be utilized more broadly in the discovery of therapies for intractable genetic diseases.

However, several subsequent validations are required to support its clinical application. As the PAM recognition range has widened, the possibility of unintended cleavage or malfunction at off-target sites must be rigorously evaluated at the Whole Genome Sequencing (WGS) level. It is also essential to evaluate delivery efficiency and long-term expression safety compared with wild-type enzymes across diverse tissue environments in mammalian cells. If future research on delivery system optimization and binding stability control proceeds in parallel, this technology is expected to become a key foundational technology that significantly accelerates the discovery of targets for genome editing therapeutics.

BACKGROUND: Amongst the genome manipulation tools based on the versatile CRISPR-Cas system, prime editing is the most prominent one as a method that enables precise insertions, deletions, and substitutions without inducing double-strand breaks. Cas12a nucleases are widely used for genome editing and nucleic acid detection, owing to their unique properties; however, their relatively long PAM requirements limit their applicability. RESULTS: We develop PAM-flexible Cas12a variants capable of functioning effectively within mammalian cells, thereby enabling the cleavage of targets previously inaccessible to Cas12a nucleases. Amongst the Lb-, As-, Mb-, and FnCas12a variants we develop, flexiAsCas12a (AsCas12a with flexible PAM recognition) is the most effective, expanding the range of recognized PAM sequences by Cas12a variants to include NATN, NCCN and GTCN sequences. Using the currently available Cas12a variants with relaxed PAM recognition (impLbCas12a, flexiAsCas12a, and enAsCas12a), we develop circular RNA-guided split prime editors and validate their functionality on non-canonical PAM sequences. CONCLUSIONS: flexiAsCas12a joins the repertoire of Cas12a PAM variants, enabling access to an increasing number of target sequences by Cas12a nucleases.

πŸ’¬Why it matters:

The newly developed flexiAsCas12a and circRNA split prime editor system directly addresses the target bottleneck in gene therapeutic development. Conventional Cas12a has a low target binding density, making it difficult to design guide RNAs that precisely match the pathogenic mutation sites of specific patients. In contrast, the new platform that recognizes NATN, NCCN, and GTCN sequences expands the range of target options across the genome by several-fold.

In particular, when transporting large prime editors into in vivo delivery vehicles with limited loading capacity, such as Adeno-Associated Virus (AAV), the split design and the high stability of circRNA create technical synergy. This can serve as a core tool for rapidly designing and verifying customized editing therapeutic candidates for single-gene mutation diseases, such as hemophilia or Duchenne muscular dystrophy, where therapeutic development has been delayed due to binding site limitations.

πŸ’¬ Comments

0 comments
Please log in to comment
Loading...

BioPlayground

Reading, linking, and lawful quotation stay open; high-speed bulk collection and unauthorized redistribution do not.

Unless stated otherwise, content rights belong to BioPlayground or the relevant rights holder.